A Multicenter Consortium to Define the Epidemiology and Outcomes of Pediatric Solid Organ Transplant Recipients With Inpatient Respiratory Virus Infection.


Journal

Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049

Informations de publication

Date de publication:
01 Jul 2019
Historique:
received: 31 08 2017
accepted: 07 02 2018
pubmed: 15 3 2018
medline: 29 2 2020
entrez: 15 3 2018
Statut: ppublish

Résumé

Respiratory virus infection (RVI) in pediatric solid organ transplant (SOT) recipients poses a significant risk; however, the epidemiology and effects of an RVI after pediatric SOT in the era of current molecular diagnostic assays are unclear. A retrospective observational cohort of pediatric SOT recipients (January 2010 to June 2013) was assembled from 9 US pediatric transplant centers. Charts were reviewed for RVI events associated with hospitalization within 1 year after the transplant. An RVI diagnosis required respiratory symptoms and detection of a virus (ie, human rhinovirus/enterovirus, human metapneumovirus, influenza virus, parainfluenza virus, coronavirus, and/or respiratory syncytial virus). The incidence of RVI was calculated, and the association of baseline SOT factors with subsequent pulmonary complications and death was assessed. Of 1096 pediatric SOT recipients (448 liver, 289 kidney, 251 heart, 66 lung, 42 intestine/multivisceral), 159 (14.5%) developed RVI associated with hospitalization within 12 months after their transplant. RVI occurred at the highest rates in intestine/abdominal multivisceral (38%), thoracic (heart/lung) (18.6%), and liver (15.6%) transplant recipients and a lower rate in kidney (5.5%) transplant recipients. RVI was associated with younger median age at transplant (1.72 vs 7.89 years; P < .001) and among liver or kidney transplant recipients with the receipt of a deceased-donor graft compared to a living donor (P = .01). The all-cause and attributable case-fatality rates within 3 months of RVI onset were 4% and 0%, respectively. Multivariable logistic regression models revealed that age was independently associated with increased risk for a pulmonary complication (odds ratio, 1.24 [95% confidence interval, 1.02-1.51]) and that receipt of an intestine/multivisceral transplant was associated with increased risk of all-cause death (odds ratio, 24.54 [95% confidence interval, 1.69-327.96]). In this study, hospital-associated RVI was common in the first year after pediatric SOT and associated with younger age at transplant. All-cause death after RVI was rare, and no definitive attributable death occurred.

Sections du résumé

BACKGROUND BACKGROUND
Respiratory virus infection (RVI) in pediatric solid organ transplant (SOT) recipients poses a significant risk; however, the epidemiology and effects of an RVI after pediatric SOT in the era of current molecular diagnostic assays are unclear.
METHODS METHODS
A retrospective observational cohort of pediatric SOT recipients (January 2010 to June 2013) was assembled from 9 US pediatric transplant centers. Charts were reviewed for RVI events associated with hospitalization within 1 year after the transplant. An RVI diagnosis required respiratory symptoms and detection of a virus (ie, human rhinovirus/enterovirus, human metapneumovirus, influenza virus, parainfluenza virus, coronavirus, and/or respiratory syncytial virus). The incidence of RVI was calculated, and the association of baseline SOT factors with subsequent pulmonary complications and death was assessed.
RESULTS RESULTS
Of 1096 pediatric SOT recipients (448 liver, 289 kidney, 251 heart, 66 lung, 42 intestine/multivisceral), 159 (14.5%) developed RVI associated with hospitalization within 12 months after their transplant. RVI occurred at the highest rates in intestine/abdominal multivisceral (38%), thoracic (heart/lung) (18.6%), and liver (15.6%) transplant recipients and a lower rate in kidney (5.5%) transplant recipients. RVI was associated with younger median age at transplant (1.72 vs 7.89 years; P < .001) and among liver or kidney transplant recipients with the receipt of a deceased-donor graft compared to a living donor (P = .01). The all-cause and attributable case-fatality rates within 3 months of RVI onset were 4% and 0%, respectively. Multivariable logistic regression models revealed that age was independently associated with increased risk for a pulmonary complication (odds ratio, 1.24 [95% confidence interval, 1.02-1.51]) and that receipt of an intestine/multivisceral transplant was associated with increased risk of all-cause death (odds ratio, 24.54 [95% confidence interval, 1.69-327.96]).
CONCLUSIONS CONCLUSIONS
In this study, hospital-associated RVI was common in the first year after pediatric SOT and associated with younger age at transplant. All-cause death after RVI was rare, and no definitive attributable death occurred.

Identifiants

pubmed: 29538674
pii: 4925905
doi: 10.1093/jpids/piy024
pmc: PMC7107524
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

197-204

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Pediatr Transplant. 2010 May;14(3):431-6
pubmed: 20214745
Influenza Other Respir Viruses. 2016 May;10(3):205-10
pubmed: 26859306
Pediatr Transplant. 2013 Aug;17(5):461-5
pubmed: 23672407
Pediatr Transplant. 2015 Sep;19(6):659-62
pubmed: 26152857
J Thorac Cardiovasc Surg. 1998 Oct;116(4):617-23
pubmed: 9766590
J Pediatric Infect Dis Soc. 2018 Dec 3;7(4):275-282
pubmed: 29106589
Transpl Infect Dis. 2009 Aug;11(4):304-12
pubmed: 19422670
Pediatr Transplant. 2013 Mar;17(2):133-43
pubmed: 23228170
Clin Transplant. 2013 Jan-Feb;27(1):E64-71
pubmed: 23278569
Am J Transplant. 2008 Jul;8(7):1567-9
pubmed: 18513273
Transpl Infect Dis. 2012 Dec;14(6):584-8
pubmed: 22998763
Clin Infect Dis. 2016 Feb 1;62(3):313-319
pubmed: 26565010
Pediatr Transplant. 2006 Nov;10(7):826-9
pubmed: 17032430
Lancet Infect Dis. 2010 Aug;10(8):521-6
pubmed: 20620116
Clin Infect Dis. 1995 Feb;20(2):394-9
pubmed: 7742447
J Heart Lung Transplant. 2010 May;29(5):582-4
pubmed: 20044274

Auteurs

Lara Danziger-Isakov (L)

Department of Pediatrics, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Ohio.

William J Steinbach (WJ)

Departments of Pediatrics and Molecular Genetics and Microbiology, Duke University, Durham, North Carolina.

Grant Paulsen (G)

Department of Pediatrics, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Ohio.

Flor M Munoz (FM)

Department of Pediatrics, Section of Infectious Diseases, Texas Children's Hospital, Baylor College of Medicine, Houston.

Leigh R Sweet (LR)

Department of Pediatrics, Section of Infectious Diseases, Texas Children's Hospital, Baylor College of Medicine, Houston.

Michael Green (M)

Division of Infectious Diseases, Children's Hospital of Pittsburgh of UPMC, and Departments of Pediatrics and Surgery, University of Pittsburgh School of Medicine, Pennsylvania.

Marian G Michaels (MG)

Division of Infectious Diseases, Children's Hospital of Pittsburgh of UPMC, and Departments of Pediatrics and Surgery, University of Pittsburgh School of Medicine, Pennsylvania.

Janet A Englund (JA)

Seattle Children's Research Institute, Seattle Children's Hospital, and University of Washington.

Alastair Murray (A)

Seattle Children's Research Institute, Seattle Children's Hospital, and University of Washington.

Natasha Halasa (N)

Division of Pediatric Infectious Diseases, Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, Tennessee.

Daniel E Dulek (DE)

Division of Pediatric Infectious Diseases, Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, Tennessee.

Rebecca Pellett Madan (RP)

Department of Pediatrics, Albert Einstein College of Medicine and Children's Hospital at Montefiore, Bronx, New York.

Betsy C Herold (BC)

Department of Pediatrics, Albert Einstein College of Medicine and Children's Hospital at Montefiore, Bronx, New York.

Brian T Fisher (BT)

Division of Infectious Diseases, Department of Pediatrics, Pennsylvania.
Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Pennsylvania.
Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH